Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Guillermo Garcia-Manero, James McCloskey, Elizabeth A. Griffiths, Karen W.L. Yee, Amer M. Zeidan, Aref Al-Kali, H. Joachim Deeg, Prapti A. Patel, Mitchell Sabloff, Mary Margaret Keating, Nancy Zhu, Nashat Y. Gabrail, Salman Fazal, Joseph Maly, Olatoyosi Odenike, Hagop Kantarjian, Amy E. DeZern, Casey L. O'Connell, Gail J. Roboz, Lambert BusqueRena Buckstein, Harshad Amin, Jasleen Randhawa, Brian Leber, Aditi Shastri, Kim Hien Dao, Aram Oganesian, Yong Hao, Harold N. Keer, Mohammad Azab, Michael R. Savona
Dive into the research topics of 'Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study'. Together they form a unique fingerprint.